A bcr-v-abl oncogene induces lymphomas in transgenic mice.

AUTOR(ES)

Hariharan, I K

RESUMO

In chronic myeloid leukemia and some cases of acute lymphoblastic leukemia, a 9;22 chromosome translocation has fused most of the c-abl oncogene to a gene designated bcr. To explore in vivo the biological effects of the chimeric gene, we introduced a facsimile of the translocation product, a bcr-v-abl gene, into the mouse germ line under the control of the immunoglobulin heavy-chain enhancer or a retroviral long terminal repeat. Some transgenic mice bearing either construct developed clonal lymphoid tumors. T lymphomas predominated, but some pre-B lymphomas developed. The transgenes were expressed in the tumors but not detectably in the lymphoid tissues of nontumorous transgenic animals, implying that transcription is activated by a low-frequency somatic event. These results demonstrate that bcr-v-abl is tumorigenic in vivo and provide a new animal model for lymphomagenesis.

Documentos Relacionados

• bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.
• The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
• Biological consequences of the BCR/ABL fusion gene in humans and mice.